GlassScriptPhysician profile
Abby B Herget
NPI 1447666466
$2,982.62
in general payments reported to CMS, 2019-2025
36 companies · $776 in 2025
The $776 reported for 2025 was more than what 81% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $432 · 2022: $506 · 2023: $575 · 2024: $695 · 2025: $776.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,045.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,045.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $486.59 | 2021-2025 | |
| Lilly USA, LLC | $337.36 | 2021-2025 | Mounjaro, Zepbound, Emgality |
| Novo Nordisk INC | $236.29 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Pfizer INC. | $190.14 | 2021-2025 | |
| Astellas Pharma US INC | $187.24 | 2021-2025 | Veozah, Myrbetriq |
| Exact Sciences Corporation | $155.73 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $122.66 | 2022-2025 | Caplyta |
| Glaxosmithkline, LLC. | $93.85 | 2022-2025 | Shingrix, Arexvy, Bexsero |
| Axsome Therapeutics, INC. | $86.38 | 2023-2024 | Sunosi, Auvelity |
| Teva Pharmaceuticals USA, INC. | $83.10 | 2021 | |
| Madrigal Pharmaceuticals | $80.82 | 2025 | Rezdiffra |
| Biohaven Pharmaceutical Holding Company LTD. | $62.60 | 2022 | |
| Alkermes, INC. | $59.46 | 2021-2023 | Vivitrol |
| Lundbeck LLC | $58.00 | 2024-2025 | Rexulti, Vyepti |
| Astrazeneca Pharmaceuticals LP | $57.04 | 2023-2025 | Breztri |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $54.45 | 2022-2025 | Evenity |
| Janssen Pharmaceuticals, INC | $53.82 | 2024-2025 | Spravato |
| Phathom Pharmaceuticals, INC. | $53.13 | 2024-2025 | Voquezna |
| Seqirus USA INC | $43.29 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Alk-Abello, INC | $41.93 | 2025 | Neffy |
| Takeda Pharmaceuticals U.S.A., INC. | $39.98 | 2021-2023 | Trintellix |
| Abbott Laboratories | $38.82 | 2023 | Freestyle Libre 3 |
| Biohaven Pharmaceuticals, INC. | $37.93 | 2021 | |
| Corium, LLC | $36.40 | 2023-2024 | Azstarys |
| Organon LLC | $34.04 | 2025 | Nexplanon |
| Irhythm Technologies, INC. | $29.17 | 2024 | Zio Monitor, Zio Xt Patch |
| Ironshore Pharmaceuticals INC. | $28.63 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $27.58 | 2022 | |
| Biogen, INC. | $27.07 | 2024 | |
| Indivior INC. | $24.00 | 2024 | Sublocade |
| Jazz Pharmaceuticals INC. | $23.74 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $22.41 | 2025 | Rexulti |
| Inspire Medical Systems, INC. | $19.13 | 2025 | Inspire |
| Radius Health, INC. | $18.99 | 2025 | |
| Phadia US INC. | $15.86 | 2024 | Immunocap |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abby Herget listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.